Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;23(1):16-18.
doi: 10.1016/S1470-2045(21)00695-1.

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era

Muhammad Bilal Abid  1
Affiliations
Comment

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era

Muhammad Bilal Abid. Lancet Oncol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

I declare no competing interests.

Comment on

References

    1. Abid MB, Mughal M, Abid MA. Coronavirus disease 2019 (COVID-19) and immune-engaging cancer treatment. JAMA Oncol. 2020;6:1529–1530. - PubMed
    1. Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195:388–398. - PMC - PubMed
    1. Caimi PF, Pacheco Sanchez G, Sharma A, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front Immunol. 2021;12 - PMC - PubMed
    1. Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134:2149–2158. - PMC - PubMed
    1. Caimi PF, Ahmed N, Rojas P, et al. Prophylactic tocilizumab before CD3/4-1bb anti-CD19 car-T cell infusion decreases incidence of severe crs without increased risk of neurotoxicity. Cytotherapy. 2020;22:S16–S17.

Substances